302 related articles for article (PubMed ID: 15110188)
1. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.
Whang YE; Yuan XJ; Liu Y; Majumder S; Lewis TD
Vitam Horm; 2004; 67():409-26. PubMed ID: 15110188
[TBL] [Abstract][Full Text] [Related]
2. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
Kandasamy K; Srivastava RK
Cancer Res; 2002 Sep; 62(17):4929-37. PubMed ID: 12208743
[TBL] [Abstract][Full Text] [Related]
3. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.
Chen X; Thakkar H; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
Oncogene; 2001 Sep; 20(42):6073-83. PubMed ID: 11593415
[TBL] [Abstract][Full Text] [Related]
4. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Mitsiades CS; Mitsiades N; Poulaki V; Schlossman R; Akiyama M; Chauhan D; Hideshima T; Treon SP; Munshi NC; Richardson PG; Anderson KC
Oncogene; 2002 Aug; 21(37):5673-83. PubMed ID: 12173037
[TBL] [Abstract][Full Text] [Related]
5. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
6. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP.
Rokhlin OW; Guseva NV; Tagiyev AF; Glover RA; Cohen MB
Prostate; 2002 Jun; 52(1):1-11. PubMed ID: 11992615
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.
Cenni V; Maraldi NM; Ruggeri A; Secchiero P; Del Coco R; De Pol A; Cocco L; Marmiroli S
Int J Oncol; 2004 Dec; 25(6):1599-608. PubMed ID: 15547696
[TBL] [Abstract][Full Text] [Related]
8. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
Aggarwal BB; Bhardwaj U; Takada Y
Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190
[TBL] [Abstract][Full Text] [Related]
9. Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation.
Kang YC; Kim KM; Lee KS; Namkoong S; Lee SJ; Han JA; Jeoung D; Ha KS; Kwon YG; Kim YM
Cell Death Differ; 2004 Dec; 11(12):1287-98. PubMed ID: 15297884
[TBL] [Abstract][Full Text] [Related]
10. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
Thakkar H; Chen X; Tyan F; Gim S; Robinson H; Lee C; Pandey SK; Nwokorie C; Onwudiwe N; Srivastava RK
J Biol Chem; 2001 Oct; 276(42):38361-9. PubMed ID: 11461904
[TBL] [Abstract][Full Text] [Related]
11. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
12. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630
[TBL] [Abstract][Full Text] [Related]
13. Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand.
Oka N; Tanimoto S; Taue R; Nakatsuji H; Kishimoto T; Izaki H; Fukumori T; Takahashi M; Nishitani M; Kanayama HO
Cancer Sci; 2006 Oct; 97(10):1093-8. PubMed ID: 16984382
[TBL] [Abstract][Full Text] [Related]
14. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways.
Secchiero P; Gonelli A; Carnevale E; Milani D; Pandolfi A; Zella D; Zauli G
Circulation; 2003 May; 107(17):2250-6. PubMed ID: 12668516
[TBL] [Abstract][Full Text] [Related]
15. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells.
Milani D; Zauli G; Rimondi E; Celeghini C; Marmiroli S; Narducci P; Capitani S; Secchiero P
J Neurochem; 2003 Jul; 86(1):126-35. PubMed ID: 12807432
[TBL] [Abstract][Full Text] [Related]
16. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation.
Bortul R; Tazzari PL; Cappellini A; Tabellini G; Billi AM; Bareggi R; Manzoli L; Cocco L; Martelli AM
Leukemia; 2003 Feb; 17(2):379-89. PubMed ID: 12592338
[TBL] [Abstract][Full Text] [Related]
17. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
[TBL] [Abstract][Full Text] [Related]
18. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2.
Alladina SJ; Song JH; Davidge ST; Hao C; Easton AS
J Vasc Res; 2005; 42(4):337-47. PubMed ID: 15985761
[TBL] [Abstract][Full Text] [Related]
19. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
20. PI-3-kinase/NF-kappaB mediated response of Jurkat T leukemic cells to two different chemotherapeutic drugs, etoposide and TRAIL.
Sabatini N; Di Pietro R; Rapino M; Sancilio S; Comani S; Cataldi A
J Cell Biochem; 2004 Oct; 93(2):301-11. PubMed ID: 15368357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
